Clinical Research and Community Engagement Core
临床研究和社区参与核心
基本信息
- 批准号:10664045
- 负责人:
- 金额:$ 31.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-03-10 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:AdoptionBiochemicalBioinformaticsBiostatistics CoreBloodBusinessesCardiometabolic DiseaseCenters of Research ExcellenceClinicClinicalClinical ResearchCollectionCommunitiesData CollectionDevelopmentDiagnosisDissemination and ImplementationEnsureEquipmentEtiologyFarmFeesFundingFutureGoalsGrantHealthcareHurricaneIndividualInstitutional Review BoardsInternationalInterventionLaboratoriesManualsMulti-Institutional Clinical TrialNursing ResearchPaperPatient RecruitmentsPeer ReviewPhasePilot ProjectsPlayPreparationPreventionProceduresProtocols documentationPublishingQuality ControlResearchResearch InfrastructureResearch Peer ReviewResearch PersonnelResearch Project GrantsResearch SupportResourcesRoleSamplingServicesSpecimenTrainingTranslational ResearchUnited States National Institutes of HealthUniversitiesUrineVisitclinical infrastructurecommunity engagementcostimplementation researchimprovedintervention deliveryoperationparticipant retentionpopulation healthprogramsprotocol developmentquality assurancereal world applicationrecruitresearch facilitysuccesstranslational pipelinetranslational research programtranslational study
项目摘要
PROJECT SUMMARY/ABSTRACT (Clinical Research and Community Engagement Core)
The Tulane COBRE for Clinical and Translational Research in Cardiometabolic Diseases (Phase 1) has
successfully supported Tulane University's efforts to increase the quality and quantity of clinical and
translational research in cardiometabolic diseases. The Clinical Research Core played a central role in the
success of COBRE Phase 1, which included seven Research Project Leaders (RPLs) and Pilot Project
Leaders (PPLs) who received one or more research grants from NIH and NSF and 310 peer-reviewed
scientific articles published by COBRE investigators. This COBRE Phase 2 application aims to further develop
and strengthen the clinical and translational research infrastructure at Tulane University and to continuously
expand and support a critical mass of investigators with expertise in clinical and translational research in
cardiometabolic diseases. In Phase 2, the Clinical Research Core will be expanded into the Clinical Research
and Community Engagement (CRCE) Core and the Bioinformatics and Biostatistics Core. The CRCE Core will
continue to support RPLs, PPLs, other COBRE investigators, and collaborators through our research clinics
and biochemical laboratories and will expand efforts to strengthen and broaden capacity for community
engagement across the translational research spectrum. The overall objectives of the CRCE Core are two-fold:
to enhance and expand an effective and robust infrastructure for clinical and translational research, including
research clinics, clinical and biochemical laboratories, and community engagement at Tulane University, and to
facilitate and support RPLs, PPLs, other COBRE investigators, and collaborators in the planning and conduct
of clinical research. To achieve these objectives, the specific aims are: 1) provide clinical research facilities and
staff for study protocol development, regulatory support, participant recruitment, intervention conduct, and data
collection for RPLs, PPLs, other COBRE investigators, and collaborators to implement their individual research
projects, 2) provide clinical and biochemical laboratory support for the collection, processing, analysis, and
storage of study specimens, 3) increase capacity for community and stakeholder engagement across the
spectrum of translational research in cardiometabolic diseases to enhance study recruitment, retention, and
dissemination and translation of study findings, and 4) develop a plan to ensure the long-term sustainability of
Core operations. The CRCE Core is critically important for the proposed COBRE Phase 2 program. All four
proposed individual Research Projects will utilize the clinical research space and staff and biochemical
laboratories. In addition, community engagement support is available to RPLs, PPLs, other COBRE
investigators, and collaborators. The CRCE Core will play a central role in assisting RPLs and PPLs with their
Research Projects and their transition into independent investigators. The Core will also play an important role
in establishing and maintaining a nationally and internationally recognized clinical and translational research
program in the etiology, prevention, diagnosis, and treatment of cardiometabolic diseases at Tulane University.
项目摘要/摘要(临床研究和社区参与的核心)
杜兰心脏代谢性疾病的临床和翻译研究(第一阶段)
成功支持杜兰大学努力提高临床和医疗服务的质量和数量
心脏代谢性疾病的翻译研究。临床研究核心在以下方面发挥了核心作用
Cobre第一阶段的成功,包括七个研究项目负责人(RPL)和试点项目
从NIH和NSF获得一项或多项研究资助并接受310项同行审查的领导者(PPL)
科布雷调查人员发表的科学文章。此Cobre第二阶段应用程序旨在进一步开发
并加强杜兰大学的临床和转化研究基础设施,并继续
扩大和支持一大批在临床和翻译研究方面具有专业知识的研究人员
心脏代谢疾病。在第二阶段,临床研究的核心将扩展到临床研究
和社区参与(CRCE)核心和生物信息学和生物统计核心。CRCE核心将
继续通过我们的研究诊所支持RPLS、PPLS、其他Cobre研究人员和合作者
和生化实验室,并将扩大努力,加强和扩大社区的能力
翻译研究领域的参与度。CRCE核心的总体目标有两个方面:
加强和扩大临床和转化研究的有效和强大的基础设施,包括
杜兰大学的研究诊所、临床和生化实验室以及社区参与,以及
协助和支持RPLs、PPLs、其他Cobre调查人员和合作者的计划和实施
临床研究的成果。为了实现这些目标,具体目标是:1)提供临床研究设施和
研究方案制定、监管支持、参与者招募、干预行为和数据的工作人员
为RPL、PPL、其他Cobre调查人员和合作者收集资料,以实施他们的个人研究
项目,2)提供临床和生化实验室支持,收集、处理、分析和
存储研究样本,3)提高社区和利益相关者参与的能力
心脏代谢性疾病的转化研究范围,以促进研究的招募、保留和
传播和翻译研究结果,以及4)制定计划,确保研究结果的长期可持续性
核心运营。CRCE核心对于拟议的Cobre第二阶段计划至关重要。四个都是
拟议的个人研究项目将利用临床研究空间和人员以及生化
实验室。此外,RPL、PPL、其他Cobre也可获得社区参与支持
调查人员和合作者。CRCE核心将发挥核心作用,协助RPL和PPL
研究项目及其向独立调查人员的过渡。核心也将发挥重要作用
在建立和维护国家和国际公认的临床和翻译研究方面
杜兰大学心脏代谢性疾病的病因、预防、诊断和治疗项目。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JING CHEN其他文献
JING CHEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JING CHEN', 18)}}的其他基金
Establishing A New Diagnostic Paradigm for Peripheral Artery Disease among Patients with Chronic Kidney Disease
建立慢性肾病患者周围动脉疾病的新诊断范式
- 批准号:
10465042 - 财政年份:2021
- 资助金额:
$ 31.3万 - 项目类别:
Establishing A New Diagnostic Paradigm for Peripheral Artery Disease among Patients with Chronic Kidney Disease
建立慢性肾病患者周围动脉疾病的新诊断范式
- 批准号:
10677577 - 财政年份:2021
- 资助金额:
$ 31.3万 - 项目类别:
Establishing A New Diagnostic Paradigm for Peripheral Artery Disease among Patients with Chronic Kidney Disease
建立慢性肾病患者周围动脉疾病的新诊断范式
- 批准号:
10186101 - 财政年份:2021
- 资助金额:
$ 31.3万 - 项目类别:
Regulation of RPE degeneration by REV-ERBalpha
REV-ERBalpha 对 RPE 变性的调节
- 批准号:
10667553 - 财政年份:2020
- 资助金额:
$ 31.3万 - 项目类别:
Regulation of RPE degeneration by REV-ERBalpha
REV-ERBalpha 对 RPE 变性的调节
- 批准号:
10218186 - 财政年份:2020
- 资助金额:
$ 31.3万 - 项目类别:
Regulation of RPE degeneration by REV-ERBalpha
REV-ERBalpha 对 RPE 变性的调节
- 批准号:
10448503 - 财政年份:2020
- 资助金额:
$ 31.3万 - 项目类别:
Regulation of RPE degeneration by REV-ERBalpha
REV-ERBalpha 对 RPE 变性的调节
- 批准号:
10029720 - 财政年份:2020
- 资助金额:
$ 31.3万 - 项目类别:
Wnt signaling-mediated control of blood-retinal barrier
Wnt信号介导的血视网膜屏障控制
- 批准号:
9918370 - 财政年份:2017
- 资助金额:
$ 31.3万 - 项目类别:
Urinary Angiotensinogen Excretion and Salt-Sensitivity of Blood Pressure
尿血管紧张素原排泄和血压的盐敏感性
- 批准号:
8697725 - 财政年份:2014
- 资助金额:
$ 31.3万 - 项目类别:
相似海外基金
CAREER: Biochemical and Structural Mechanisms Controlling tRNA-Modifying Metalloenzymes
职业:控制 tRNA 修饰金属酶的生化和结构机制
- 批准号:
2339759 - 财政年份:2024
- 资助金额:
$ 31.3万 - 项目类别:
Continuing Grant
Leveraging releasable aryl diazonium ions to probe biochemical systems
利用可释放的芳基重氮离子探测生化系统
- 批准号:
2320160 - 财政年份:2023
- 资助金额:
$ 31.3万 - 项目类别:
Standard Grant
Diurnal environmental adaptation via circadian transcriptional control based on a biochemical oscillator
基于生化振荡器的昼夜节律转录控制的昼夜环境适应
- 批准号:
23H02481 - 财政年份:2023
- 资助金额:
$ 31.3万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Systematic manipulation of tau protein aggregation: bridging biochemical and pathological properties
tau 蛋白聚集的系统操作:桥接生化和病理特性
- 批准号:
479334 - 财政年份:2023
- 资助金额:
$ 31.3万 - 项目类别:
Operating Grants
Converting cytoskeletal forces into biochemical signals
将细胞骨架力转化为生化信号
- 批准号:
10655891 - 财政年份:2023
- 资助金额:
$ 31.3万 - 项目类别:
Enhanced Biochemical Monitoring for Aortic Aneurysm Disease
加强主动脉瘤疾病的生化监测
- 批准号:
10716621 - 财政年份:2023
- 资助金额:
$ 31.3万 - 项目类别:
Biochemical Mechanisms for Sustained Humoral Immunity
持续体液免疫的生化机制
- 批准号:
10637251 - 财政年份:2023
- 资助金额:
$ 31.3万 - 项目类别:
Structural and biochemical investigations into the mechanism and evolution of soluble guanylate cyclase regulation
可溶性鸟苷酸环化酶调节机制和进化的结构和生化研究
- 批准号:
10604822 - 财政年份:2023
- 资助金额:
$ 31.3万 - 项目类别:
Chemical strategies to investigate biochemical crosstalk in human chromatin
研究人类染色质生化串扰的化学策略
- 批准号:
10621634 - 财政年份:2023
- 资助金额:
$ 31.3万 - 项目类别:
EAGER: Elastic Electronics for Sensing Gut Luminal and Serosal Biochemical Release
EAGER:用于感测肠腔和浆膜生化释放的弹性电子器件
- 批准号:
2334134 - 财政年份:2023
- 资助金额:
$ 31.3万 - 项目类别:
Standard Grant